Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOMA: Maintenance Bevacizumab +/- Metronomic Chemotherapy in mCRC
NCT02271464Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Mar 2012
- Primary completion
- Mar 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, cyclophosphamide in metastatic colorectal cancer (mCRC), sponsored by Azienda Ospedaliero-Universitaria Pisana. Started Mar 2012; status: completed.
02
Drugs
capecitabinecyclophosphamide
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02271464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271464.